ALGINATE FILM CONTAINING A TRIPTAN
Patent Information
- Application Number
- DE602017092563
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2016-11-15
- Filing Date
- 2017-11-14
- Publication Date
- 2025-11-05
- Estimated Expiration
- 2037-11-14
AI Technical Summary
Current sumatriptan formulations for migraine treatment are invasive, poorly tolerated by nauseous patients, and fail to achieve consistent plasma concentrations for effective pain relief, with nasal sprays being particularly ineffective and oral tablets poorly absorbed.
A film comprising an alginate salt of a monovalent cation and sumatriptan or its pharmaceutically acceptable salt, designed for administration to the oral cavity, which ensures rapid and consistent plasma concentration of sumatriptan above 10 ng/mL within 60 minutes.
The alginate film achieves significantly higher plasma levels of sumatriptan within 60 minutes, providing effective migraine relief for a greater proportion of patients compared to existing nasal spray formulations.